• 1. Estimation of hydrogen sulfide from crude petroleum: a unique invention using a simple chemosensor?
  Shampa Kundu,Prithidipa Sahoo New J. Chem., 2019,43, 12369-12374
• 2. Enantiomeric helical TiO2 nanofibers modulate different peptide assemblies and subsequent cellular behaviors?
  Xu Jie,Deng Xu,Weili Wei RSC Adv., 2019,9, 29149-29153
• 3. Estimating and correcting interference fringes in infrared spectra in infrared hyperspectral imaging
  Ghazal Azarfar,Ebrahim Aboualizadeh,Nicholas M. Walter,Simona Ratti,Camilla Olivieri,Alessandra Norici,Michael Nasse,Achim Kohler,Mario Giordano Analyst, 2018,143, 4674-4683
• 4. Evolved polymerases facilitate selection of fully 2′-OMe-modified aptamers?
  Zhixia Liu,Tingjian Chen,Floyd E. Romesberg Chem. Sci., 2017,8, 8179-8182
• 5. Evidence of pre-micellar aggregates in aqueous solution of amphiphilic PDMS–PEO block copolymer?
  Domenico Lombardo,Gianmarco Munaò,Pietro Calandra,Luigi Pasqua,Maria Teresa Caccamo Phys. Chem. Chem. Phys., 2019,21, 11983-11991

Introduction to 6-bromopyrimidine-4-carboxamide (CAS No: 1209458-24-1)

6-bromopyrimidine-4-carboxamide, identified by its Chemical Abstracts Service (CAS) number 1209458-24-1, is a significant compound in the field of pharmaceutical chemistry and medicinal research. This heterocyclic organic molecule features a pyrimidine core substituted with a bromine atom at the 6-position and an amide functional group at the 4-position. Its unique structural attributes make it a valuable intermediate in the synthesis of various biologically active molecules, particularly in the development of targeted therapies.

The pyrimidine scaffold is a fundamental motif in nucleic acid chemistry, closely mimicking the structure of natural purines and pyrimidines found in DNA and RNA. This structural similarity has positioned 6-bromopyrimidine-4-carboxamide as a key building block in the design of nucleoside analogs and antiviral agents. The presence of the bromine atom at the 6-position enhances its reactivity, allowing for further functionalization through cross-coupling reactions such as Suzuki-Miyaura or Buchwald-Hartwig couplings, which are pivotal in constructing complex drug molecules.

The amide group at the 4-position introduces additional versatility, enabling transformations such as hydrolysis to yield carboxylic acids or amidation to form more sophisticated derivatives. These modifications are critical in fine-tuning the pharmacokinetic and pharmacodynamic properties of drug candidates. Recent advancements in medicinal chemistry have highlighted the utility of 6-bromopyrimidine-4-carboxamide in generating novel inhibitors targeting enzymes involved in cancer metabolism and inflammation.

In oncology research, 6-bromopyrimidine-4-carboxamide has been explored as a precursor for small-molecule inhibitors of kinases and other enzymes implicated in tumor proliferation. For instance, studies have demonstrated its role in synthesizing compounds that selectively inhibit tyrosine kinases, which are overexpressed in many solid tumors. The bromine substituent facilitates palladium-catalyzed cross-coupling reactions, enabling the introduction of aryl or heteroaryl groups that modulate binding affinity to target proteins.

Moreover, the compound has shown promise in developing treatments for inflammatory diseases. Researchers have leveraged its structural framework to create molecules that modulate inflammatory signaling pathways by inhibiting key transcription factors. The amide functionality allows for tuning solubility and metabolic stability, critical factors for drug efficacy and bioavailability. Preclinical studies have indicated that derivatives of 6-bromopyrimidine-4-carboxamide exhibit anti-inflammatory properties comparable to established therapeutics while offering novel mechanisms of action.

The synthesis of 6-bromopyrimidine-4-carboxamide typically involves multi-step organic transformations starting from commercially available pyrimidine precursors. Key steps include halogenation at the 6-position followed by carboxylation at the 4-position via methods such as nucleophilic aromatic substitution or directed ortho-metalation. Advances in synthetic methodologies have improved yields and reduced reaction times, making large-scale production more feasible for research and industrial applications.

Recent publications highlight innovative applications of 6-bromopyrimidine-4-carboxamide in drug discovery beyond traditional kinase inhibition. For example, researchers have utilized it to develop proteasome inhibitors, which are crucial in treating certain blood cancers by disrupting protein degradation pathways. The compound’s ability to undergo further derivatization has enabled the creation of libraries of diverse analogs for high-throughput screening, accelerating the identification of lead compounds with optimized pharmacological profiles.

The growing interest in 6-bromopyrimidine-4-carboxamide underscores its versatility as a pharmacophore. Its integration into drug development pipelines reflects its potential to address unmet medical needs across multiple therapeutic areas. As computational chemistry and artificial intelligence continue to revolutionize molecular design, compounds like 6-bromopyrimidine-4-carboxamide are being employed to generate structure-based predictions for novel drug candidates with enhanced efficacy and reduced toxicity.

In conclusion, 6-bromopyrimidine-4-carboxamide (CAS No: 1209458-24-1) represents a cornerstone molecule in modern medicinal chemistry. Its unique structural features and reactivity make it indispensable for synthesizing biologically relevant compounds with therapeutic potential. Ongoing research efforts are likely to uncover further applications, reinforcing its significance as a key intermediate in pharmaceutical innovation.

• 6345-42-2(4,6-Pyrimidinedicarboxamide)
• 28648-86-4(Pyrimidine-4-carboxamide)
• 1209458-85-4(2-Bromopyrimidine-4-carboxamide)
• 1805550-15-5(6-Bromopyrimidine-4-carbaldehyde)
• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)